Belgium-based UCB hit the mark in the company’s Phase III clinical trial assessing zilucoplan as a potential treatment for adults with generalized myasthenia gravis, a rare autoimmune disease. Vanda Pharmaceuticals’ late-stage study of tradipitant as a treatment for the symptoms of gastroparesis, a digestive disorder, failed to meet the trial’s primary endpoint.
Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
Arcadia Consumer Healthcare Inc., (formerly Kramer Laboratories Inc.) a recognized leader in the consumer healthcare industry, announced that the company completed the acquisition of the U.S. rights to the Kaopectate brand from Sanofi.
The U.S. Food and Drug Administration approved Blueprint Medicines Corp.’s oral therapy to treat a rare form of cancer that affects the stomach and small intestine.
Shares of Evoke Pharma plunged more than 40 percent after the company announced the U.S. FDA issued a Complete Response Letter regarding the gastroparesis treatment Gimotti.
The old adage that drinking beer before wine prevents hangovers turns out to be a myth, German researchers say.
